Court Revives Regenxbio, UPenn Patent Suit Against Sarepta
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy SRPT?
Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to rise
18 Analyst Rating
4 Buy
10 Hold
4 Sell
Hold
Current: 15.870
Low
5.00
Averages
20.80
High
45.00
Current: 15.870
Low
5.00
Averages
20.80
High
45.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
Sarepta Launches Duchenne Scholarship Program for 2026-2027
- Scholarship Program Launch: Sarepta Therapeutics has announced the opening of the Route 79 Duchenne Scholarship Program for the 2026-2027 academic year, offering scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings, aimed at supporting the educational aspirations of this unique community.
- Clear Application Criteria: Applicants must be accepted to or enrolled in an accredited college or vocational school in the U.S. and must be diagnosed with Duchenne or have a sibling diagnosed with the condition, ensuring fairness and targeted support for educational opportunities.
- Independent Review Process: Scholarship recipients are selected by an independent committee, which evaluates applications without considering whether the applicant has received treatment from Sarepta, thereby enhancing the program's credibility and transparency in the selection process.
- Historical Impact: Since its inception nine years ago, the Route 79 Scholarship Program has empowered numerous young individuals to pursue their academic dreams, reflecting Sarepta's ongoing commitment to supporting those affected by Duchenne muscular dystrophy and reinforcing its leadership position in precision genetic medicine.
See More
Sarepta Therapeutics Invites Applications for the 9th Annual Route 79 Duchenne Scholarship Program
Announcement of Application Call: Sarepta Therapeutics has announced a call for applications for the 9th Annual Route 79, the Duchenne Scholarship Program.
Focus on Duchenne Muscular Dystrophy: The program aims to support individuals affected by Duchenne muscular dystrophy through educational scholarships.
See More
Sarepta Therapeutics Stock Falls 9% Following Larger-than-Expected Q4 Loss
Company Performance: Sarepta Therapeutics shares fell by 9% following a larger-than-expected loss in the fourth quarter.
Market Reaction: The significant drop in share value indicates investor disappointment with the company's financial results.
See More
Sarepta Therapeutics Reports Earnings Miss and Management Transition
- Earnings Miss: Sarepta Therapeutics reported an adjusted loss of $3.58 per share, significantly worse than Wall Street's estimate of a $1.31 loss, while sales reached $442.93 million, exceeding the consensus of $391.92 million; however, sales fell 33% year-over-year, primarily due to a $273.8 million drop in Elevidys net product revenue following the company's decision to suspend shipments to non-ambulatory patients in June 2025.
- Management Transition: CEO Douglas Ingram announced his plan to retire by the end of 2026 or upon the appointment of his successor, as disclosed in an SEC filing, prompting the company to initiate a search for a new CEO, which could lead to increased stock volatility in the near term.
- Analyst View: While the company has guided for stable PMO revenue in 2026, analyst Sami Corwin expresses hesitation due to concerns over the marketing authorization of Vyondys 53 and Amondys 45 following the recent failure of the ESSENCE trial; William Blair reiterates a Market Perform rating, viewing limited near-term upside potential for the stock.
- Technical Analysis: The stock is currently trading 3.5% below its 20-day simple moving average and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term, with an RSI of 50.00 suggesting neutral market sentiment, while a MACD of -0.10 below its signal line at -0.05 indicates bearish pressure, with key resistance at $20.00 and support at $15.00.
See More
Wall Street Opens Cautiously Amid China Market Concerns
- Cautious Market Sentiment: Despite Nvidia's strong earnings report, Wall Street traders are cautious ahead of the open due to concerns over its revenue from China, with Nasdaq futures down 0.1% and Dow futures down 0.2%.
- Merger Developments in Focus: Investors are closely watching Warner Bros. Discovery's upcoming earnings report, while speculation arises that Netflix may abandon its bid for the company, with its co-CEO heading to the White House to discuss regulatory issues, highlighting the market's keen interest in merger dynamics.
- Software Giants' Guidance Miss: Salesforce's fiscal 2027 revenue guidance fell short of Wall Street expectations despite a strong Q4 earnings report, negatively impacting investor sentiment and leading to a decline in confidence in the software sector.
- Monitoring Economic Data: Investors will be attentive to the weekly jobless claims data set to be released at 8:30 a.m. ET, along with Federal Reserve Vice Chair Michelle Bowman's testimony before Congress, which could influence market perceptions of the economic outlook.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
Sarepta Launches Duchenne Scholarship Program for 2026-2027
- Scholarship Program Launch: Sarepta Therapeutics has announced the opening of the Route 79 Duchenne Scholarship Program for the 2026-2027 academic year, offering scholarships of up to $5,000 to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings, aimed at supporting the educational aspirations of this unique community.
- Clear Application Criteria: Applicants must be accepted to or enrolled in an accredited college or vocational school in the U.S. and must be diagnosed with Duchenne or have a sibling diagnosed with the condition, ensuring fairness and targeted support for educational opportunities.
- Independent Review Process: Scholarship recipients are selected by an independent committee, which evaluates applications without considering whether the applicant has received treatment from Sarepta, thereby enhancing the program's credibility and transparency in the selection process.
- Historical Impact: Since its inception nine years ago, the Route 79 Scholarship Program has empowered numerous young individuals to pursue their academic dreams, reflecting Sarepta's ongoing commitment to supporting those affected by Duchenne muscular dystrophy and reinforcing its leadership position in precision genetic medicine.
See More
Sarepta Therapeutics Invites Applications for the 9th Annual Route 79 Duchenne Scholarship Program
Announcement of Application Call: Sarepta Therapeutics has announced a call for applications for the 9th Annual Route 79, the Duchenne Scholarship Program.
Focus on Duchenne Muscular Dystrophy: The program aims to support individuals affected by Duchenne muscular dystrophy through educational scholarships.
See More
Sarepta Therapeutics Stock Falls 9% Following Larger-than-Expected Q4 Loss
Company Performance: Sarepta Therapeutics shares fell by 9% following a larger-than-expected loss in the fourth quarter.
Market Reaction: The significant drop in share value indicates investor disappointment with the company's financial results.
See More
Sarepta Therapeutics Reports Earnings Miss and Management Transition
- Earnings Miss: Sarepta Therapeutics reported an adjusted loss of $3.58 per share, significantly worse than Wall Street's estimate of a $1.31 loss, while sales reached $442.93 million, exceeding the consensus of $391.92 million; however, sales fell 33% year-over-year, primarily due to a $273.8 million drop in Elevidys net product revenue following the company's decision to suspend shipments to non-ambulatory patients in June 2025.
- Management Transition: CEO Douglas Ingram announced his plan to retire by the end of 2026 or upon the appointment of his successor, as disclosed in an SEC filing, prompting the company to initiate a search for a new CEO, which could lead to increased stock volatility in the near term.
- Analyst View: While the company has guided for stable PMO revenue in 2026, analyst Sami Corwin expresses hesitation due to concerns over the marketing authorization of Vyondys 53 and Amondys 45 following the recent failure of the ESSENCE trial; William Blair reiterates a Market Perform rating, viewing limited near-term upside potential for the stock.
- Technical Analysis: The stock is currently trading 3.5% below its 20-day simple moving average and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term, with an RSI of 50.00 suggesting neutral market sentiment, while a MACD of -0.10 below its signal line at -0.05 indicates bearish pressure, with key resistance at $20.00 and support at $15.00.
See More
Wall Street Opens Cautiously Amid China Market Concerns
- Cautious Market Sentiment: Despite Nvidia's strong earnings report, Wall Street traders are cautious ahead of the open due to concerns over its revenue from China, with Nasdaq futures down 0.1% and Dow futures down 0.2%.
- Merger Developments in Focus: Investors are closely watching Warner Bros. Discovery's upcoming earnings report, while speculation arises that Netflix may abandon its bid for the company, with its co-CEO heading to the White House to discuss regulatory issues, highlighting the market's keen interest in merger dynamics.
- Software Giants' Guidance Miss: Salesforce's fiscal 2027 revenue guidance fell short of Wall Street expectations despite a strong Q4 earnings report, negatively impacting investor sentiment and leading to a decline in confidence in the software sector.
- Monitoring Economic Data: Investors will be attentive to the weekly jobless claims data set to be released at 8:30 a.m. ET, along with Federal Reserve Vice Chair Michelle Bowman's testimony before Congress, which could influence market perceptions of the economic outlook.
See More
